PBA
PCVX icon

Paradigm Biocapital Advisors’s Vaxcyte PCVX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-276,800
Closed -$31.6M – 37
2024
Q3 		$31.6M Buy
+276,800
New +$24.9M 1.07% 28

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Paradigm Biocapital Advisors's PCVX Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Vaxcyte (PCVX) stake by 18% in Q1 2026, buying an estimated $39.4M and bringing the position to 4,793,020 shares worth $279M. The position accounts for 5.69% of the portfolio, ranked #4.

Paradigm Biocapital Advisors first reported a position in PCVX in Q1 2024 and has held it in 9 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Paradigm Biocapital Advisors held 4,793,020 shares of Vaxcyte worth $279M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 725,000 Vaxcyte shares in Q1 2026, an estimated $39.4M.
  • Vaxcyte made up 5.69% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #4 holding.
  • Paradigm Biocapital Advisors first reported a position in Vaxcyte in Q1 2024 and has held it in 9 quarters since.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.